The global cerebral infraction drugs market is estimated to grow at ~7% CAGR over the forecast period, i.e., 2022 – 2030. Cerebral Infraction, also known as stroke, occurs when the supply of blood is disrupted in brain, due to rupture of blood vessels or clotting in the vessels. The growth of the market can be attributed to the unhealthy lifestyle which causes cerebral infarction, such as, stress, unhealthy eating, lack of physical activity, and smoking. Increasing patient pool of hypertension, diabetes, and obesity, is the primary growth driver for the market growth. According in a report by World Health Organization (WHO), 1.13 billion people suffer from hypertension worldwide. Additionally, in 2019, over 1.5 million deaths were caused by diabetes. The scope for R&D activities for developing novel drugs is estimated to further boost the market growth. Moreover, growing healthcare facilities and a rising number of hospitals along with increasing investment in the healthcare sector is also anticipated to fuel the market growth. The growing prevalence of cerebrovascular diseases, such as, ischemic stroke, is also a major growth driver for the market. According to the data by the Center of Disease Control and Prevention (CDC), around 87% of all strokes are ischemic strokes, in which the blood flow to the brain gets blocked.
The market is segmented by drug class into tissue plasminogen activators (tPA), anticoagulants, and others, out of which, the tissue plasminogen activators (tPA) segment is anticipated to hold the largest share in the global cerebral infraction drugs market over the forecast period on account of increasing use of tPA to breakdown clots. Tissue plasminogen activator is a type of protein involved in the breakdown of blood clots. On the basis of distribution channel, the hospital segment is estimated to gain significant share over the forecast period, owing to the growing patient pool of cerebral infarction, coupled with high credibility of hospitals. CLICK TO DOWNLOAD SAMPLE REPORT
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
On the basis of geographical analysis, the global cerebral infraction drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America region is estimated to witness highest growth over the forecast period on the back of high obesity and hypertension rate in the population of United States and Canada. Moreover, high healthcare expenditure in the region, is further estimated to boost the market growth. According to a report by the World Health Organization (WHO), as of 2018, the per capita healthcare expenditure of North America valued USD 10,050.279.
The market in the Asia Pacific region is estimated to witness highest CAGR over the forecast period, owing to increasing geriatric population, and advancing healthcare system. According to the data by the World Bank, the population above 65 years of age in India crossed 90,719,952 in 2020, while, it crossed 167,808,567 in China. Moreover, rising healthcare expenditure and investment in R&D activities is estimated to boost the market growth.
The global cerebral infraction drugs market is further classified on the basis of region as follows:
Our in-depth analysis of the global cerebral infraction drugs market includes the following segments:
FREQUENTLY ASKED QUESTIONS
Growing prevalence of stroke, and other cerebrovascular disease along with increasing investment in developing new drugs to boost the market growth.
The market is anticipated to attain a CAGR ~7% over the forecast period, i.e., 2022 – 2030.
Complications related to stroke are estimated to hamper the market growth.
The market in the Asia Pacific is estimated to provide most business opportunities owing to the increasing geriatric population, and developing healthcare system.
The major players in the market are Novartis AG, Sanofi-aventis Groupe, Abbott Laboratories, Merck & Co., Inc., Siemens Healthcare GmbH, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Pfizer Inc., and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by diagnosis, drug class, distribution channel, and by region.
The hospital segment is anticipated to hold largest market size over the forecast period and display significant growth opportunities owing to the growing patient pool in hospitals.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization